Literature DB >> 2574304

Serological effects of Edmonston-Zagreb, Schwarz, and AIK-C measles vaccine strains given at ages 4-5 or 8-10 months.

O Tidjani1, B Grunitsky, N Guérin, D Lévy-Bruhl, N Lecam, C Xuereff, K Tatagan.   

Abstract

To examine the value of vaccinating children against measles at age 4-5 months three groups of children in Togo were randomly assigned to receive high-dose Edmonston-Zagreb, high-dose Schwarz, or AIK-C vaccines at that age. Two other groups were vaccinated at age 8-10 months, with either the standard Schwarz vaccine or the same batch of AIK-C as for early immunisation. For the 55% of children who were seronegative before vaccination at age 4-5 months seroconversion rates were 96% with the AIK-C, 94% with the Edmonston-Zagreb, and 50% with the high-dose Schwarz. The immune response rates for children who were seropositive before vaccination were estimated to be around 50% with the high-dose Edmonston-Zagreb and AIK-C strains and 10% with the Schwarz strain. Seroconversion rates for vaccination at 8-10 months were 87% for the AIK-C and 68% for the Schwarz strains. Thus vaccination with the high-dose Edmonston-Zagreb or the AIK-C strain at 4-5 months was as good as vaccination with the AIK-C strain at 8-10 months and better than vaccination with the standard dose Schwarz strain at 8-10 months. These findings require confirmation by further investigations, particularly epidemiological studies, but they already provide evidence that the administration of AIK-C and high-dose Edmonston-Zagreb strains at 4-5 months is at least as effective as vaccination with the standard strains at 8-10 months.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574304     DOI: 10.1016/s0140-6736(89)91967-3

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  11 in total

Review 1.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

2.  Long-term survival in trial of medium-titre Edmonston-Zagreb measles vaccine in Guinea-Bissau: five-year follow-up.

Authors:  P Aaby; I M Lisse; H Whittle; K Knudsen; J Thaarup; A Poulsen; M Sodemann; M Jakobsen; L Brink; U Gansted
Journal:  Epidemiol Infect       Date:  1994-04       Impact factor: 2.451

3.  Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana.

Authors:  F K Nkrumah; M Osei-Kwasi; S K Dunyo; K A Koram; E A Afari
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

4.  Molecular cloning and complete nucleotide sequence of genomic RNA of the AIK-C strain of attenuated measles virus.

Authors:  T Mori; K Sasaki; H Hashimoto; S Makino
Journal:  Virus Genes       Date:  1993-02       Impact factor: 2.332

5.  Sex-specific differences in mortality after high-titre measles immunization in rural Senegal.

Authors:  P Aaby; B Samb; F Simondon; K Knudsen; A M Seck; J Bennett; L Markowitz; P Rhodes; H Whittle
Journal:  Bull World Health Organ       Date:  1994       Impact factor: 9.408

6.  Immune response to simultaneous administration of a combined measles, mumps and rubella vaccine with booster doses of diphtheria-tetanus and poliovirus vaccine.

Authors:  G Giammanco; S Li Volti; I Salemi; G Giammanco Bilancia; L Mauro
Journal:  Eur J Epidemiol       Date:  1993-03       Impact factor: 8.082

7.  Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350.

Authors:  Hoyin Mok; Xing Cheng; Qi Xu; James R Zengel; Bandita Parhy; Jackie Zhao; C Kathy Wang; Hong Jin
Journal:  Open Virol J       Date:  2012-02-16

8.  Simultaneous Administration of Recombinant Measles Viruses Expressing Respiratory Syncytial Virus Fusion (F) and Nucleo (N) Proteins Induced Humoral and Cellular Immune Responses in Cotton Rats.

Authors:  Yoshiaki Yamaji; Akihito Sawada; Yosuke Yasui; Takashi Ito; Tetsuo Nakayama
Journal:  Vaccines (Basel)       Date:  2019-03-04

9.  Recombinant Measles AIK-C Vaccine Strain Expressing the prM-E Antigen of Japanese Encephalitis Virus.

Authors:  Akira Higuchi; Hiroko Toriniwa; Tomoyoshi Komiya; Tetsuo Nakayama
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

10.  Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis.

Authors:  Sara Carazo; Marie-Noëlle Billard; Amélie Boutin; Gaston De Serres
Journal:  BMC Infect Dis       Date:  2020-03-29       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.